Intra-Cellular Therapies Inc.
www.intracellulartherapies.com
Latest From Intra-Cellular Therapies Inc.
Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression
Firm will discuss Phase III data with the US FDA, calling results from a successful Phase III monotherapy study robust despite second Phase III study's failure. Lumateperone is under review for schizophrenia, with a 27 September action date.
Keeping Track: FDA Clears Motegrity And Second Herceptin Biosimilar, But Rebuffs SpecGx's Oxycodone
Priority Reviews At US FDA: From Third Quarter Spikes To A Third Quarter Trough
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Intra-Cellular Therapies Inc.
- Senior Management
-
Sharon Mates, PhD, Chmn. & CEO
Lawrence J Hineline, VP, Fin. & CFO
Allen A Fienberg, PhD, VP, Bus. Dev.
Robert E Davis, PhD, SVP, CSO
Andrew Satlin, MD, EVP, CMO
Mark Neumann, EVP, Chief Commercial Officer - Contact Info
-
Intra-Cellular Therapies Inc.
Phone: (646) 440-9333
430 East 29th St.
Ste. 900
New York, NY 10016
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice